Mefloquine

證據等級: L5

預測適應症: 0 個

Mefloquine (DB00358): Drug Repurposing Analysis — No Predictions Available

One-Sentence Summary

Mefloquine is an antimalarial agent (DrugBank ID: DB00358) currently not marketed in Canada. This Evidence Pack contains no TxGNN repurposing predictions and has critical data gaps across indication, MOA, and safety fields. A formal drug repurposing evaluation cannot be completed without supplementary data collection.

Quick Overview

Item	Content
Original Indication	Not documented in this Evidence Pack
Predicted New Indication	No predictions returned
TxGNN Prediction Score	N/A
Evidence Level	L5 — Model prediction only; no predictions generated
Canada Market Status	Not Marketed
Number of DINs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known information, Mefloquine is a quinoline-methanol antimalarial agent (DrugBank ID: DB00358); however, since neither original indications nor MOA data are present in the supplied Evidence Pack, a formal mechanistic analysis linking the original indication to a new indication cannot be conducted.

The TxGNN prediction pipeline did not return any repurposing candidates for this drug in the current run. This may result from incomplete input mapping (e.g., DrugBank ID not resolving to a knowledge graph node), a missing disease-drug edge in the training graph, or a pipeline upstream error. The query_log confirms only one successful DrugBank query was executed, and no collector sources (ClinicalTrials, PubMed, etc.) were queried.

Until a prediction is available and the above data gaps are resolved, it is not possible to assess whether Mefloquine’s mechanism is applicable to any new indication.

Safety Considerations

Please refer to the package insert for safety information.

The Evidence Pack reports [Data Gap] for all of: key warnings, contraindications, and drug interactions. No DDI records were found (query_status: not_found). Safety data must be retrieved before any downstream evaluation proceeds.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack for Mefloquine contains blocking data gaps — no TxGNN repurposing predictions were generated, original indication and MOA data are absent, and no safety profile is available. Proceeding to any repurposing evaluation under these conditions would be methodologically unsound.

To proceed, the following is needed:

[Blocking — DG001] Retrieve the package insert (from Health Canada Product Monograph or equivalent) to extract key warnings and contraindications; this must be resolved before safety screening can begin
[High — DG002] Query DrugBank API for Mefloquine (DB00358) to obtain MOA, pharmacodynamics, and toxicity data
Re-run TxGNN predictions for Mefloquine — verify that DB00358 is correctly mapped to a knowledge graph node and that the prediction pipeline completes without errors; check data/processed/repurposing_candidates.csv for output
Populate original indications — Mefloquine’s approved indication (antimalarial) should be retrieved from Health Canada’s Drug Product Database and documented in the Evidence Pack
Expand collector queries — run ClinicalTrials.gov, PubMed, and DrugBank collectors against Mefloquine once predictions are available
Verify jurisdiction mapping — confirm that the taiwan_regulatory field is correctly populated with Canadian DIN data (current record shows 0 DINs and no licence entries)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.